Varenicline Tablet, Film Coated
Product Images NDC 27241-174

12 FDA label images from Ajanta Pharma Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 27241-174). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Varenicline-structure (Varenicline Structure)

Varenicline-structure (Varenicline Structure)
Chemical structure of Varenicline, the active ingredient of this prescription drug. The diagram shows the molecular arrangement including core rings and attached functional groups relevant to Varenicline tartrate.*
FDA Label Image

Varenicline_figure1 (Varenicline Fig1)

Varenicline_figure1 (Varenicline Fig1)
A bar chart titled 'Continuous Abstinence, Weeks 9 through 12' comparing the percentage of abstinence for different treatments across five studies. Treatments include Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Placebo, Varenicline Flexible, Bupropion SR 150 mg BID, and Placebo. Each treatment bar has error bars indicating variability. The x-axis lists the treatments and studies, while the y-axis shows percentage abstinence from 0% to 60%.*
FDA Label Image

Varenicline-figure2 (Varenicline Figure2)

Varenicline-figure2 (Varenicline Figure2)
A bar chart titled 'Figure 2: Continuous Abstinence, Weeks 9 through 52' showing percentage data across four studies. Each study compares continuous abstinence rates for Varenicline tablets or flexible dosing, Bupropion SR 150 mg BID (in studies 4 and 5), and placebo, represented with different bar patterns, including error bars indicating variability. The y-axis shows percentage from 0% to 35%. The x-axis labels indicate study numbers and treatment groups.*
FDA Label Image

Varenicline-figure3 (Varenicline Figure3)

Varenicline-figure3 (Varenicline Figure3)
A line graph showing continuous abstinence rates during nontreatment follow-up over weeks for Varenicline 1 mg tablets taken twice daily compared to placebo. The y-axis represents the percentage of continuous abstinent users, and the x-axis shows weeks of nontreatment follow-up. The Varenicline group maintains higher abstinence rates than the placebo group throughout the period.*
FDA Label Image

Starting-month-box (Varenicline 0 5mg And 1mg)

Starting-month-box (Varenicline 0 5mg And 1mg)
Packaging label for Varenicline Tablets, oral film-coated tablets available in a starting month box for the first 4 weeks. The label indicates two strengths: 0.5 mg and 1 mg tablets, with a supply including 11 tablets of the 0.5 mg strength and 42 tablets of the 1 mg strength. The product is manufactured by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc. The label includes usage instructions for pharmacists and a barcode.*
FDA Label Image

Continuing-pack (Varenicline Continuing Pack)

Continuing-pack (Varenicline  Continuing Pack)
A dosing calendar illustration for Varenicline tablets depicting a 28-day treatment plan divided into four weekly sections. Each week shows days numbered with morning and evening dosing times, with the first week marked for 0.5 mg tablets and subsequent weeks for 1 mg tablets. The layout provides daily checkboxes to track tablet intake.*
FDA Label Image

0.5mg-and-1mg (Varenicline 0 5mg 1mg)

0.5mg-and-1mg (Varenicline  0 5mg 1mg)
Packaging labels for Varenicline Tablets by Ajanta Pharma USA Inc., showing two strengths: 0.5 mg and 1 mg. The 0.5 mg label has a yellow background, while the 1 mg labels have a blue background. Each label includes the NDC number, detailed dosage information, manufacturer details, a barcode, and storage instructions.*
FDA Label Image

Continuing-month-box (Varenicline Continuing Month Box)

Continuing-month-box (Varenicline Continuing Month Box)
Packaging label for Varenicline Tablets, film-coated oral tablets containing 1 mg strength. The label indicates a continuing month box with 56 tablets for 4 continuing weeks and is labeled for prescription use only. Manufactured by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc.*
FDA Label Image

1mg-continuing (Varenicline Continuing Week)

1mg-continuing (Varenicline  Continuing Week)
Blister card image for Varenicline Tablets showing a daily dosage schedule for four weeks. Each week panel indicates dosing instructions to take 1 mg tablets in the morning and evening, except the first week where it is only prescribed beginning with 1 tablet. The card is divided into sections labeled Day 1 to Day 28, with designated morning and evening dose slots, and the tablets are film-coated oral dosage forms. Each section is numbered 1 to 4 to represent weekly pill administration.*
FDA Label Image

1mg-continuing (Varenicline Continuing 1mg)

1mg-continuing (Varenicline  Continuing 1mg)
Packaging label for Varenicline Tablets 1 mg film-coated oral tablets. The blue label includes product and manufacturer information, indicating it is produced by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc. It also displays storage instructions and a barcode. The label contains four identical panels labeled 1 to 4, each specifying the 1 mg strength and tablet details.*
FDA Label Image

0-5mg (Varenicline 0 5mg)

0-5mg (Varenicline  0 5mg)
Varenicline Tablets 0.5 mg film coated tablets label, containing 56 tablets. The label includes dosage strength, drug name, NDC 27241-173-56, manufacturer Ajanta Pharma Limited (India), and marketer Ajanta Pharma USA Inc. Contains storage instructions, child-resistant warnings, and pharmacist dispensing guidance. Barcode and a blank unvarnished OPZ area are also visible.*
FDA Label Image

1mg (Varenicline 1mg)

1mg (Varenicline 1mg)
Label for Varenicline Tablets 1 mg by Ajanta Pharma USA Inc. The label indicates 56 film-coated tablets per package and includes NDC 27241-174-56. Storage instructions and warnings about child resistance are present. The label also shows a barcode, lot and expiration placeholders, and manufacturer details noting the product is made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.